Related Experiment Videos
SGLT2 Inhibitors and Uric Acid Homeostasis
1Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Abstract:
A relationship between metabolic disorders and hyperuricemia is well established. The nature of the relationship-risk factor, causal agent, or byproduct-remains unclear. Recent studies of sodium-glucose transporter 2 inhibitors (SGLT2i's) have established that this pharmacological intervention is beneficial to patients with hyperglycemia and type 2 diabetes mellitus (T2D) and also against the common cardio and renal comorbidities associated with diabetes. Hyperuricemia, or high plasma uric acid levels, is one of the comorbidities mitigated with SGLT2i treatment, raising the potential for using SGLT2i's as part of the treatment for gout and hyperuricemia. However, the mechanisms underlying the lower plasma urate levels and increased uricosuria produced with SGLT2i's remains poorly understood. Here, we review the renal physiology of glucose and uric acid transport, the renal consequences of hyperglycosuria and diabetes, the benefits and physiology of SGLT2i use, and discuss several potential mechanisms that may be responsible for the favorable uricosuric effect observed in those treated with SGLT2i's.
Insights
Sodium-glucose transporter 2 inhibitors (SGLT2i) lower uric acid levels, benefiting patients with metabolic disorders like type 2 diabetes. Further research is needed to understand the exact mechanisms behind this uricosuric effect.
Area of Science:
- Nephrology
- Endocrinology
- Metabolic Disorders
Background:
- A link between metabolic disorders and hyperuricemia is known, but the precise relationship is unclear.
- Hyperuricemia is a common comorbidity in type 2 diabetes mellitus (T2D).
- Sodium-glucose transporter 2 inhibitors (SGLT2i) offer benefits for hyperglycemia, T2D, and associated cardio-renal conditions.
Purpose of the Study:
- To review the renal physiology of glucose and uric acid transport.
- To discuss the renal consequences of hyperglycosuria and diabetes.
- To explore potential mechanisms for the uricosuric effect of SGLT2i.
Main Methods:
- Literature review of renal physiology.
- Analysis of SGLT2i effects on glucose and uric acid.
- Discussion of potential uricosuric mechanisms.
Main Results:
- SGLT2i treatment is associated with reduced plasma uric acid levels.
- SGLT2i treatment increases urinary uric acid excretion (uricosuria).
- The exact mechanisms driving these uricosuric effects require further elucidation.
Conclusions:
- SGLT2i may hold potential as a therapeutic option for gout and hyperuricemia.
- Understanding SGLT2i's uricosuric mechanisms could optimize treatment strategies.
- Further investigation into SGLT2i's renal effects is warranted.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Dipeptidyl Peptidase 4 Inhibitors
Phase II Reactions: Glucuronidation
Urinary Tract Calculi III: Medical Management
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones